Hansen Medical, Inc., announced plans to commence a clinical trial to evaluate its flexible catheter Sensei X Robotic System in patients with ventricular tachycardia. Ventricular tachycardia, or VT, is an abnormal rapid heartbeat, which can be life-threatening because it may lead to ventricular fibrillation, asystole, and sudden cardiac death.
The Sensei X Robotic System features a flexible catheter with remotely steerable distal tips designed make it easier for medical practitioners to navigate a catheter for therapeutic intervention.
The clinical trial, which is called Early Robotic Ablation by Substrate Elimination of Ventricular Tachycardia (ERASE-VT), is designed to enroll 200 patients with implantable defibrillators at up to eight sites in Europe. The study is being sponsored by Imperial College of Science Technology and Medicine out of the Cardiology Department at St. Mary's Hospital.
Clinicians are hoping to reduce or eliminate episodes of VT, and to evaluate the effects of robotic ablation on patient hospital length of stay, mortality, and quality of life.